https://orcid.org/0000-0003-0809-7604
Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Christian Kjer Heerfordt, Josefin Eklöf, Pradeesh Sivapalan, Truls Sylvan Ingebrigtsen, Tor Biering-Sørensen, Zitta Barrella Harboe, Jesper Koefod Petersen, Christian Østergaard Andersen, Jonas Bredtoft Boel, Anne Kathrine Bock, Alexander G Mathioudakis, John R Hurst, Shailesh Kolekar, Sofie Lock Johansson, Jette Marie Bangsborg, Jens Otto Jarløv, Ram Benny Dessau, Christian Borbjerg Laursen, Michael Perch & Jens-Ulrik Stæhr Jensen. (2023) Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 373-384.
Read now
Read now
Jae-Hwa Choi, Keun-Bae Jeong, You Hyun Park, Iseul Yu, Seok Jeong Lee, Myoung Kyu Lee, Sang-Ha Kim, Won-Yeon Lee, Suk Joong Yong & Ji-Ho Lee. (2021) Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 3229-3237.
Read now
Read now
Thomas P Lodise & Sanjay Sethi. (2021) Response to the Letter to the Editor Regarding “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Response to Letter]. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1227-1229.
Read now
Read now
Neil C Barnes, Dave Singh & David A Lipson. (2021) Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1299-1301.
Read now
Read now
Articles from other publishers (7)
Yuan Wu, Mengfen Huang, Jinyao Zhong, Yue Lu, Kao Gan, Rongyuan Yang, Yuntao Liu, Jiqiang Li & Jiankun Chen. (2023) The clinical efficacy of type 2 monoclonal antibodies in eosinophil-associated chronic airway diseases: a meta-analysis. Frontiers in Immunology 14.
Crossref
Crossref
Ralph Brattsand & Olof Selroos. (2022) May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?. Pulmonary Pharmacology & Therapeutics 77, pages 102167.
Crossref
Crossref
Iseul Yu, Sunmin Park, Se Hwa Hong, Min-Seok Chang, Seok Jeong Lee, Suk Joong Yong, Won-Yeon Lee, Sang-Ha Kim & Ji-Ho Lee. (2022) Risk of Tuberculosis Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Study. Journal of Personalized Medicine 12:7, pages 1189.
Crossref
Crossref
Hanaa Shafiek, Javier Verdú, Amanda Iglesias, Lluisa Ramon-Clar, Nuria Toledo-Pons, Carla Lopez-Causape, Carlos Juan, Pablo Fraile-Ribot, Antonio Oliver & Borja G Cosio. (2021)
Inhaled corticosteroid dose is associated with
Pseudomonas aeruginosa
infection in severe COPD
. BMJ Open Respiratory Research 8:1, pages e001067.
Crossref
Crossref
Marc Miravitlles, Ariadna Auladell-Rispau, Mònica Monteagudo, Juan Carlos Vázquez-Niebla, Jibril Mohammed, Alexa Nuñez & Gerard Urrútia. (2021) Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. European Respiratory Review 30:160, pages 210075.
Crossref
Crossref
Cheng-Yi Wang & Chih-Cheng Lai. (2021) The association between inhaled corticosteroid and osteoporosis and fracture. European Respiratory Journal 57:6, pages 2100216.
Crossref
Crossref
Pradeesh Sivapalan, András Bikov & Jens-Ulrik Jensen. (2021) Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease. Diagnostics 11:2, pages 236.
Crossref
Crossref